Allogene Therapeutics, Inc. (ALLO) has a negative trailing P/E of -3.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -31.88%, forward earnings yield 39.22%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -550,140.9 | 0.00 | -550,140.93 | 0.00 | - |
| 2018 | -11.4 | 0.00 | 3.43 | 0.00 | - |
| 2019 | -14.2 | 0.63 | 4.17 | 0.00 | - |
| 2020 | -12.1 | -0.89 | 2.81 | 0.00 | - |
| 2021 | -11.1 | 0.31 | 2.19 | 17.76 | - |
| 2022 | -2.6 | -0.03 | 1.35 | 5,771.76 | - |
| 2023 | -1.5 | 0.13 | 0.98 | 5,302.65 | - |
| 2024 | -1.6 | 0.04 | 0.98 | 18,861.34 | - |
| 2025 | -1.6 | 0.05 | 1.03 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $0.00 | $0.00 | $-2K | - |
| 2018 | $-7.31 | $0.00 | $-211.51M | - |
| 2019 | $-1.83 | $0.00 | $-184.59M | - |
| 2020 | $-1.94 | $0.00 | $-250.22M | - |
| 2021 | $-1.89 | $114.09M | $-182.05M | -159.6% |
| 2022 | $-2.32 | $156K | $-340.41M | -218214.1% |
| 2023 | $-2.09 | $95K | $-327.27M | -344489.5% |
| 2024 | $-1.32 | $22K | $-257.59M | -1170863.6% |
| 2025 | $-0.87 | $0.00 | $-190.89M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.80 | $-0.99 – $-0.52 | $16.67K | $16.67K – $16.67K | 8 |
| 2027 | $-0.79 | $-0.99 – $-0.44 | $21.37M | $21.37M – $21.37M | 8 |
| 2028 | $-0.70 | $-0.99 – $-0.26 | $110.22M | $110.22M – $110.22M | 11 |
| 2029 | $-0.03 | $-0.03 – $-0.03 | $340.12M | $340.12M – $340.12M | 4 |
| 2030 | $0.90 | $0.90 – $0.90 | $645.96M | $645.96M – $645.96M | 4 |
